Neurogene Inc. (NGNE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 88.50M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 18.22M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -121.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $88.50M | (m) | $18.22M | $-121.35M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $82.40M | (m) | $13.76M | $-110.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $75.01M | $0.00 | $14.18M | $-103.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $69.72M | $0.00 | $13.31M | $-97.31M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $68.76M | $0.00 | $12.42M | $-95.69M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $65.14M | (m) | $11.32M | $-89.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $60.92M | $925.00K | $8.32M | $-82.61M | (m) | 6585.62% | 899.46% | (m) | (m) |
| 2024-09-30 | $57.75M | (m) | $6.19M | $-75.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $53.08M | (m) | $4.10M | $-68.86M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $47.65M | (m) | $2.17M | $-61.33M | $13.00K | (m) | (m) | -4717.46× | Reported |
| 2023-12-31 | $44.39M | (m) | $1.42M | $-55.58M | $12.00K | (m) | (m) | -4631.92× | Reported |
| 2023-09-30 | $17.88M | (m) | $3.73M | $-38.02M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $26.74M | (m) | $5.59M | $-46.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $38.12M | (m) | $7.57M | $-58.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $41.13M | (m) | $8.83M | $-59.10M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $9.80M | $-60.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $10.98M | $-61.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $11.58M | $-61.12M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $11.56M | $-60.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $10.78M | $-58.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $9.26M | $-44.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $7.36M | $-39.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $5.62M | $-33.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $4.06M | $-29.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $7.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $7.29M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $7.68M | $-70.96M | $1.00K | (m) | (m) | -70959.00× | Reported |
| 2019-09-30 | (m) | (m) | $7.85M | $-67.90M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $3.74M | $-23.58M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $31.39M | (m) | $4.46M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $41.79M | $25.00M | $4.70M | $-32.62M | $4.00K | 167.16% | 18.79% | -8156.00× | Reported |
| 2018-09-30 | $50.78M | (m) | $4.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $48.52M | (m) | $4.98M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $41.00M | (m) | $4.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $36.27M | (m) | $3.84M | (m) | $4.00K | (m) | (m) | (m) | Reported |
| 2017-09-30 | $32.84M | (m) | $3.43M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $30.52M | (m) | $2.74M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $29.28M | (m) | $2.16M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $28.38M | (m) | $1.97M | (m) | $1.00K | (m) | (m) | (m) | Reported |
| 2016-09-30 | $24.18M | (m) | $1.77M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $21.73M | (m) | $1.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $16.11M | (m) | $1.67M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $15.80M | (m) | $1.51M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $18.20M | (m) | $1.41M | (m) | $17.59K | (m) | (m) | (m) | Reported |
| 2015-06-30 | $19.83M | (m) | $1.22M | (m) | $15.59K | (m) | (m) | (m) | Reported |
| 2015-03-31 | $20.77M | (m) | $982.19K | (m) | $13.59K | (m) | (m) | (m) | Reported |
| 2014-12-31 | $18.08M | (m) | $854.19K | (m) | $461.59K | (m) | (m) | (m) | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $7.60M | (m) | $349.32K | (m) | $42.92K | (m) | (m) | (m) | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $6.05M | (m) | $351.32K | (m) | $9.47K | (m) | (m) | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |